ISRG at 45x Earnings, Below Its Own Five-Year Average P/E

Intuitive Surgical trades around $393.33 as I write this, 34.9% below its 52-week high of $604 and only 20% above its 52-week low of $329. That is a large gap for a company that still grew quarterly revenue 19% year over year in its last report. Something moved a lot faster than the underlying business did, and figuring out which one is wrong is the whole question here.

The short version: on 2026-07-16, Intuitive beat both lines. Quarterly earnings came in at $2.80 a share against a Street estimate near $2.50, and revenue landed above consensus. The stock fell anyway, and fell hard in the sessions around the print, extending a decline that had already left the shares down roughly 29% year to date coming into the report. Beating estimates and dropping is not a contradiction if the guidance attached to the beat disappoints, and that is roughly what happened here.

My thesis: the multiple did the correcting, not the business. At 45.1 times trailing earnings, Intuitive now trades below its own five-year average of 69.7 times, which is the first time in a long stretch that has been true. The da Vinci franchise did not get smaller. The price investors will pay for it got smaller, and that gap between “the stock fell” and “the earnings power fell” is where I think the opportunity, and the risk, actually sit.

What broke on July 16

Management held full-year procedure growth guidance at 13.5% to 15.5% rather than raising it, even after a quarter that beat on both revenue and earnings. Analysts had room to expect an upgrade given the beat, and they did not get one. Coverage after the print pointed to a mix of reasons: softer signals on US da Vinci procedure volumes, more conservative commentary tied to ACA-related coverage uncertainty, and a Class II recall affecting certain da Vinci surgical components. None of those three is, by itself, a franchise-ending problem. Together, in one earnings call, they were enough to knock the stock down by more than the company’s own five-year average earnings-day move of 8.9%.

That is the part worth sitting with. A guidance hold is not a guidance cut. The range Intuitive gave in July is still a real growth range, and 13.5% procedure growth on an installed base this size is not a company running out of demand. It is a company being asked to clear a bar that had quietly moved higher because the stock had run for years without much doubt attached to the price.

The instrument-and-accessory engine

Intuitive’s economics have not changed shape. It places da Vinci systems at a comparatively thin margin, then earns high-margin, recurring revenue for years afterward on the instruments and accessories consumed in every procedure, plus service contracts on the installed base. Gross margin ran 66.0% last period, down from 67.5% a year earlier, a fairly small step down given the mix pressure from newer, lower-margin system placements and the timing of the recall. Operating margin held at 29%, and net margin was also 29%, both close to where this business has run for years. The underlying statements are on Intuitive Surgical’s financials page if you want to check them.

Net income reached $2.9 billion over the trailing year, up from $2.3 billion, a 26% increase that outran revenue growth of 21%. That kind of gap, profit growing faster than sales, usually means either cost discipline or a favorable shift in mix toward the higher-margin instrument and service lines, and for a razor-and-blade business like this one, the second explanation fits better than the first.

The reason the recurring piece matters is simple: procedure growth on the existing base, not new system placements, is what compounds that recurring revenue. New placements are the visible number every quarter. The number that actually drives five years of earnings from here is procedure volume on the systems already installed. A hospital that already owns three da Vinci systems and starts running more procedures on them is worth more to Intuitive over time than one new hospital buying its first system, dollar for dollar, because the second one is pure margin flow-through on instruments already priced.

Revenue for the trailing year reached $10.1 billion, up from $8.4 billion the year before, a 21% increase, and the run rate implied by the latest quarter is $11.6 billion. That is not the profile of a business absorbing a demand shock. It is the profile of a business that grew fast enough that a guide held rather than raised reads like bad news by comparison.

A multiple that finally matches its own history

I have made a version of this argument before about paying a premium for a business that keeps compounding, most recently on Microsoft at 27.5 times earnings, where the question was whether the premium is buying real durability or just habit. Intuitive is a cleaner case for the premium, because there is close to no direct competitor operating at its scale in general soft-tissue robotic surgery, and retraining a hospital’s surgical staff off da Vinci and onto a rival platform takes years, not quarters. That is a real switching cost, not a marketing line.

What changed is the price of admission. At a forward P/E of 39.1 times, versus a current 45.1 times trailing, the market is pricing continued earnings growth, and at a price-to-sales multiple of 12.2 against a five-year average near 18.0, the revenue side of the valuation has compressed even more than the earnings side. Price to book sits at 7.4 versus a five-year average of 9.5. Every one of those three ratios points the same direction: cheaper than its own recent history. None of them says Intuitive is cheap in absolute terms or cheap relative to the broader market; they say it is meaningfully cheaper than Intuitive Surgical itself has traded.

Wall Street’s price targets have not moved nearly as much as the stock. The average target across 21 analysts sits at $490, which is 25% above the current price, and 86% of those analysts rate it a buy. The low estimate in that group is $391, essentially where the stock trades now, which tells you even the most cautious sell-side view does not see much further downside baked in.

A quant downgrade the price targets don’t explain

Here is the uncertainty I cannot resolve cleanly. Intuitive’s quant grade, the kind I have written about in my review of how those ratings actually work, moved from a C to a D over the same stretch that analysts kept their price targets high and their buy ratings intact. Quant systems weight momentum, estimate revisions, and short-term profitability trends more heavily than a discretionary analyst does, and a downgrade like this usually means at least one of those factors turned negative even while the long-term story held up on paper.

I read that divergence as a signal that the market’s algorithmic and human views of this stock are not in agreement right now, which is unusual for a name this widely covered. It could mean the quant model is catching something in estimate revisions that will show up in the numbers before analysts formally cut targets. It could also mean the model is overweighting a single volatile quarter and will drift back toward a C once the July move rolls out of its lookback window. I do not have a clean way to tell which explanation is right from here, and I would rather say that plainly than pretend the tension resolves itself.

Where I could be wrong, and the number that would prove it

The bull case rests on the idea that July was a guidance-driven overreaction to a business whose underlying demand is intact. The bear case is that the ACA-related uncertainty and softer US procedure signals cited around the print are the leading edge of real demand softening rather than simply cautious language from a management team playing it safe. Short interest sits at only 2.2% of the float, so the market as a whole is not positioned for a collapse. That is a low bar to clear, and it says little about which side is right.

Given the size of the July move against an average earnings-day swing of 8.9%, this is not a position to size the way you would a utility. I wrote about the mechanics of that trade-off in how I size a position when beta runs high, and the short version applies here: a stock that can move 14% in a session earns a smaller slot in a portfolio than its growth rate alone would suggest, regardless of how good the underlying business is.

The specific number I will use to check this thesis is the next procedure-growth print against that 13.5% to 15.5% full-year range. If the next quarter tracks toward the low end of that band, or if management trims the range rather than holding it again, I would take that as evidence the deceleration is real and that 45.1 times trailing earnings is still not cheap enough for a monopoly whose growth rate is now shrinking. If procedure growth instead holds mid-range or better, the July selloff will look, in hindsight, like exactly what the multiple math above suggests: a repricing of sentiment, not of the business.

Metric	Value	Context
Price	$393.33	34.9% below the 52-week high of $604
P/E (TTM)	45.1x	five-year average 69.7x
P/E (forward)	39.1x	implies continued earnings growth
P/S (current)	12.2x	five-year average 18.0x
Revenue (TTM)	$10.1 billion	up 21% from $8.4 billion
Net income (TTM)	$2.9 billion	up 26% from $2.3 billion
Analyst target (avg)	$490	25% above current price, 86% buy-rated
Quant grade	D	down from C

Analysis and opinion only, not investment advice. Figures come from Intuitive Surgical’s filings on SEC EDGAR and its investor site; valuation multiples are approximate and were checked on September 18, 2026.

Sources: Price-to-earnings ratio (SEC Investor.gov glossary) (https://www.investor.gov/introduction-investing/investing-basics/glossary/price-earnings-pe-ratio) · How to read a company's 10-K (SEC Investor.gov) (https://www.investor.gov/introduction-investing/investing-basics/glossary/10-k)